Ropes & Gray advised Kiniksa Pharmaceuticals, Ltd., in a strategic collaboration with Huadong Medicine Co. Ltd.’s wholly owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd.,
Under the terms of the collaboration, Kiniksa will receive $22 million upfront and is eligible to receive up to approximately $640 million in specified development, regulatory and sales-based milestones. Kiniksa is also eligible to receive tiered royalties on annual net sales. Huadong Medicine will obtain exclusive rights and responsibility for the development and commercialization of ARCALYST and mavrilimumab in the Asia Pacific region including Greater China, South Korea, Australia, and 18 other countries, but excluding Japan. Kiniksa will otherwise retain all existing development and commercialization rights for both assets.
The Ropes & Gray team was led by IP transactions partner Hannah England (Freeman) and included tax partners Brenda Coleman (London) and David Saltzman (Boston), life sciences regulatory & enforcement partner Katherine Wang (Shanghai), litigation & enforcement partner Andy Dale (Hong Kong), and litigation & enforcement counsel David Yiding Chen (Shanghai).
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.